3,3-diphenylpropylamine: has antiextensor effect & worsens clonic seizure produced by pentylenetetrazole; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 79698 |
| CHEMBL ID | 609579 |
| SCHEMBL ID | 158098 |
| SCHEMBL ID | 2551931 |
| MeSH ID | M0066367 |
| Synonym |
|---|
| 5586-73-2 |
| nsc137832 |
| nsc-137832 |
| benzenepropanamine, .gamma.-phenyl- |
| 3,3-diphenylpropylamine |
| TIMTEC1_004202 |
| 3,3-diphenylpropylamine, 97% |
| HMS1545O22 |
| bdbm35932 |
| BRD-K56942431-001-01-8 |
| CHEMBL609579 |
| inchi=1/c15h17n/c16-12-11-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,15h,11-12,16h2 |
| kiszteoelcmzpy-uhfffaoysa- |
| 3,3-di(phenyl)propan-1-amine |
| alpha-(2-aminoethyl)diphenylmethane |
| D1855 |
| 3,3-diphenylpropan-1-amine |
| STK802367 |
| AKOS000120343 |
| 3,3-diphenylpropylammonium |
| A830845 |
| nsc 137832 |
| 3-3-diphenylpropylamine |
| ec 226-984-3 |
| unii-c31e561s64 |
| einecs 226-984-3 |
| c31e561s64 , |
| FT-0614092 |
| AB01166409-03 |
| BBL027697 |
| SCHEMBL158098 |
| a-(2-aminoethyl)diphenylmethane |
| 3.3-diphenylpropylamine |
| 3,3 diphenylpropylamine |
| (3,3-diphenylpropyl)amine |
| 3,3-diphenyl-propylamine |
| SCHEMBL2551931 |
| J56.243B , |
| 3,3-diphenyl-1-propanamine # |
| propylamine, 3,3-diphenyl- |
| mfcd00008202 |
| DTXSID30204458 |
| F2190-0402 |
| iem-2011 |
| .gamma.-phenylbenzenepropanamine |
| NCGC00326467-01 |
| Q4634054 |
| CCG-356441 |
| STR05806 |
| AMY30667 |
| SB79179 |
| EN300-20205 |
| Z104477262 |
| PD065608 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 7.5860 | 0.0000 | 0.3855 | 10.0000 | AID1799359; AID454689 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 5.1720 | 0.0000 | 0.5110 | 10.0000 | AID1799359; AID454690 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID454689 | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in cells | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. |
| AID454690 | Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1799359 | Radioligand Binding Assay from Article 10.1016/j.bmc.2009.08.016: \\Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.\\ | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.21) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||